[{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AMY109","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"LUCA Science","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"LUCA Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LUCA Science \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"LUCA Science \/ University of Oxford"},{"orgOrder":0,"company":"LUCA Science","sponsor":"Fast Track Initiative","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"LUCA Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LUCA Science \/ Fast Track Initiative","highestDevelopmentStatusID":"4","companyTruncated":"LUCA Science \/ Fast Track Initiative"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : AMY109 is a novel therapeutic antibody with a recycling function that binds to IL-8 (an inflammatory cytokine) and improves inflammation and fibrosis in endometriosis.

                          Product Name : AMY109

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 24, 2023

                          Lead Product(s) : AMY109

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Proceeds from financing will also be used to establish a robust manufacturing system based on its proprietary Mitochondrial Isolation Technology platform, a novel method for intact, shelf-stable and highly functional isolated mitochondria as a biopharmac...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 06, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Preclinical

                          Sponsor : Fast Track Initiative

                          Deal Size : $30.3 million

                          Deal Type : Series B Financing

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : This collaboration was formed in order to realise this solution and seeks to address this by specifically delivering therapeutics to the placenta, combining unique technology developed at LUCA Science with extensive placental research experience at the U...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 09, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Preclinical

                          Sponsor : University of Oxford

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank